RECURSION PHARMACEUTICALS, INC. Net Income Loss

Quick Answer

RECURSION PHARMACEUTICALS, INC. reported Net Income Loss of -$644.76 million for the year ending 2025.

  • RECURSION PHARMACEUTICALS, INC. showed a decrease of -39.1% in Net Income Loss from 2024 to 2025.
  • This data is from RECURSION PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
  • XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 7 years of available data (2019 to 2025), RECURSION PHARMACEUTICALS, INC.'s Net Income Loss has declined by 942.0%.
  • Historical annual values: Fiscal year 2025: -$644.76 million | Fiscal year 2024: -$463.66 million | Fiscal year 2023: -$328.07 million | Fiscal year 2022: -$239.48 million | Fiscal year 2021: -$186.48 million | Fiscal year 2020: -$87.01 million | Fiscal year 2019: -$61.88 million.
  • Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: